We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Adam Glassman

Adam R Glassman MS

Director, DRCR.net Coordinating Center, Jaeb Center for Health Research, Tampa, FL

Adam R. Glassman has worked at the Jaeb Center for Health Research in Tampa, FL since 2003. After receiving his master’s degree in statistics with an emphasis in biostatistics he joined the Jaeb Center as a biostatistician for the NIH-funded Diabetic Retinopathy Clinical Research Network (DRCR.net).  In 2006, he became the Assistant Director of the DRCR.net Coordinating Center under the principal direction of Dr. Roy Beck, MD, PhD.  Since 2009, Mr. Glassman has been the Principal Investigator and Director of the DRCR.net Coordinating Center.  He is also currently the Director of Research Quality Assurance for the Jaeb Center for Health Research.  He has served as the principal investigator for the coordinating center on over 20 NIH funded studies and 3 JDRF funded studies.  He has co-authored over 75 per reviewed publications and is a peer-reviewer to multiple journals.  Mr. Glassman has a voluntary faculty appointment as an Assistant Instructor at the University of South Florida’s Department of Ophthalmology.  He is on the advisory board for the Cochrane Eyes and Vision group and is on the editorial board for JAMA-Ophthalmology and Retina Journal.  Mr. Glassman has been a member of the Society for Clinical Trials since 2004.    

Disclosures

Financial Disclosures: Grants from the National Institutes of Health and Genentech during the conduct of the study; nonfinancial support from Genentech and Allergan during the conduct of the study; and grants from Regeneron outside the submitted work.